Biosimilars are safe and effective medications for treating many illnesses such as arthritis and cancer. Learn about biosimilars and how they benefit patients.

A biosimilar, or biosimilar drug, is a medicine that is very close in structure and function to a biologic medicine. Learn more about biosimilars here.

2025年2月14日 · There are currently 65 biosimilars approved by the U.S. Food and Drug Administration (FDA). The most recent biosimilar approval was Avtozma (tocilizumab-anoh) on January 24, 2025. What is a Biosimilar?

2023年1月24日 · Biosimilar drugs are a growing subset of biologics being developed as a way to access the medications you need at a lower cost. Biosimilar medications are highly similar in structure, safety, and effectiveness to an original (reference) biologic medication.

Biosimilars increase access to lifesaving medications at potentially lower costs. Explore the website to learn more about biosimilars and to access all FDA’s educational resources for health...

After the expiry of the patent of approved recombinant drugs (e.g., insulin, human growth hormone, interferons, erythropoietin, monoclonal antibodies and more) any other biotech company can develop and market these biologics (thus called biosimilars).

This page includes a chart of the approved biosimilar and interchangeable products. The approval of biosimilar products can improve access to care for patients by increasing the number of...

2025年2月12日 · Biosimilars are meant to be more affordable than the reference product. They are expected to help the U.S. healthcare system and consumers save money, but biosimilar products are still very expensive and unaffordable for …

A biosimilar is a biological medicine highly similar to another already approved biological medicine (the 'reference medicine'). Biosimilars are approved according to the same standards of pharmaceutical quality, safety and efficacy that apply to all biological medicines.

A biosimilar is a safe, effective and less-costly biologic medicine that is highly similar to a previously approved biologic medicine (known as a “reference product”) currently on the market. Biosimilars have scientifically comparable quality, safety and efficacy to their reference product.